Intellia Therape Stock Price, News & Analysis

Intellia Therapeutics (NASDAQ:NTLA) recently showcased significant preclinical advancements in its CRISPR/Cas9 genome editing platform at the ESGCT Annual Congress. Key highlights included the development of immune-evading allogeneic T cells, effective lipid nanoparticle delivery methods, and successful gene therapy results in non-human primates for treating alpha-1 antitrypsin deficiency (AATD). These findings support the company's strategy to progress its therapeutic candidates, including NTLA-5001 for acute myeloid leukemia, set to initiate clinical trials by year-end.

Intellia and SparingVision have announced a strategic collaboration to utilize Intellia's CRISPR/Cas9 technology for developing ocular therapies targeting three significant diseases. Intellia will grant SparingVision exclusive rights to its technology, receiving a 10% equity stake and potential milestone payments of up to $200 million per product. Additionally, Intellia may secure US commercialization rights for two targets. The collaboration aims to leverage both companies' strengths in genomic medicine and address unmet medical needs in ophthalmology. An investor webcast will provide further details.

Intellia Therapeutics (NASDAQ:NTLA) has presented key findings at the 29th Annual Congress of the European Society of Gene & Cell Therapy. The company showcased its proprietary allogeneic T cell therapy platform designed to address immune rejection in therapeutic candidates for cancer and autoimmune diseases. Significant advancements include a lipid nanoparticle-based CRISPR/Cas9 delivery system and the first reported consecutive in vivo gene insertion and knockout in non-human primates aimed at treating alpha-1 antitrypsin deficiency (AATD). This work positions Intellia at the forefront of genome editing therapeutics.

Intellia Therapeutics has received authorization from New Zealand's MEDSAFE to initiate a Phase 1/2 clinical study for NTLA-2002, a CRISPR/Cas9-based therapeutic aimed at treating hereditary angioedema (HAE). NTLA-2002 is designed to inactivate the KLKB1 gene, potentially providing a one-time treatment to prevent debilitating attacks associated with HAE. Patient enrollment is expected to start by year-end, with further regulatory applications planned globally. The program builds on insights gained from previous trials on NTLA-2001 for ATTR amyloidosis.

Intellia Therapeutics (NASDAQ:NTLA) will present at Chardan’s 5th Annual Genetic Medicines Conference on October 4, 2021, at 10:30 a.m. ET. This clinical-stage genome editing company is focused on developing curative therapeutics using CRISPR/Cas9 technology through in vivo and ex vivo methods. A live webcast of the presentation will be available on their website approximately 15 minutes prior to the start. A replay will be accessible for 14 days following the event.

Intellia Therapeutics (NASDAQ:NTLA) announced the FDA's acceptance of the IND application for NTLA-5001, its first ex vivo CRISPR-engineered therapy targeting Wilms’ Tumor 1 (WT1) for acute myeloid leukemia (AML). This milestone paves the way for a Phase 1/2a clinical study, expected to start patient screening by year-end, focusing on AML patients post-first-line therapy. The therapy aims to improve the five-year survival rate, currently below 30%. The study will involve up to 54 participants across two dosing categories, assessing safety and anti-tumor efficacy.

Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage genome editing company, will participate in two virtual healthcare investor conferences in September 2021. The first will be at the Wells Fargo Healthcare Conference on September 9 at 10:40 am ET, followed by the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 am ET. Live webcasts of the presentations will be available on Intellia's website, with replays accessible for 14 days post-event. Intellia focuses on curative therapeutics powered by CRISPR/Cas9 technology.

Intellia Therapeutics has made significant strides in its CRISPR gene-editing programs, with promising interim Phase 1 data for NTLA-2001 showing a maximum 96% reduction in serum TTR levels for ATTR amyloidosis. The company is poised to initiate Phase 1 trials for NTLA-2002 and NTLA-5001 this year. Financially, Intellia ended Q2 2021 with $551.3 million in cash and raised an additional $648.1 million from a follow-on offering. Despite a net loss of $68.8 million, Intellia's strong financial position supports ongoing and future development efforts.

Intellia Therapeutics (NASDAQ:NTLA) will present its Q2 2021 financial results and operational highlights on August 5, 2021, at 8 a.m. E.T. The conference call will provide insights into its progress in developing CRISPR/Cas9-based therapeutics. Interested participants can join via U.S. or international dialing, with a live webcast available. A replay will be accessible on Intellia's website starting noon E.T. on the same day. The company focuses on curative therapies using both in vivo and ex vivo genome editing techniques.